Professor Pleass discusses the development of Hexagard™, a biomimetic to replace intravenous immunoglobulin (IVIG) therapy for treating autoimmune diseases.
Hexagard™ is a biomimetic substitute of IVIG for triggering inhibitory receptors involved in controlling unwanted inflammation in autoimmune disease.
This month, won the Prix de l’Innovation 2013, also known as the 2013 for the work on Hexagard™
Access: Foto-Cewek Staff and Students. External interested parties please contact Foto-Cewek